NCCN Guideline Updates in Clear-Cell RCC

October 4, 2024

By Moshe Ornstein, MD, MA
Karine Tawagi, MD

Opinion

Video

Medical experts will discuss the updated NCCN guidelines favoring ipilimumab + plus nivolumab for patients with favorable risk, including the data supporting this change and its the potential impact on the disease landscape.

EP: 1.Overview of RCC: Clear-Cell and Non–clear Cell

EP: 2.Challenges in Treating RCC From Community and Academic Settings

EP: 3.Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates

EP: 4.KEYNOTE-B61: Clinical Implications of Efficacy and Safety Data in Practice

EP: 5.nccRCC: Alternative Therapies

EP: 6.Role of Histology and Data in Selecting Optimal Therapy in nccRCC

EP: 7.AE Management of IO/TKI and Future of nccRCC

EP: 8.KEYNOTE-564: Pembrolizumab as Adjuvant Therapy

Now Viewing

EP: 9.NCCN Guideline Updates in Clear-Cell RCC

EP: 10.Best Treatment Selection in Clear-Cell RCC

Video content above is prompted by the following:

NCCN guidelines have been updated to reflect ipilimumab + plus nivolumab as a preferred regimen in patients with favorable risk. What data supported this change, and how do you see it affecting the disease landscape?

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!